Kamada Ltd KMDA 深 滬
等待開盤 01-28 09:30:00 美东时间
8.87
+0.310
+3.62%
華盛通- 最 高8.87
- 今 開8.77
- 成交量 10.72万股
- 最 低 8.6856
- 昨 收 8.56
- 總市值 5.12亿
- 52周最高 8.955
- 市盈率 靜 35.47
- 換手率 0.00%
- 52周最低 5.54
- 委 比 -7.83%
- 總股本 5768.16万
- 歷史最高 17.75
- 量 比 1.23
- 振 幅 2.15%
- 歷史最低 2.82
- 每 手 1
- 風險率 0.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kamada forecasts double-digit profitable growth in 2026
Kamada forecasts 2026 revenues of $200M – $205M, compared to estimates of 200.7M and adjusted EBITDA of $50M –$53M. The 2026 outlook implies year-over-year growth of 13% in revenues and 23% in adjuste...
01-08 00:49
Kamada Sees FY2026 Sales $200.000M-$205.000M vs $200.598M Est
Kamada (NASDAQ:KMDA) sees FY2026 sales of $200.000 million-$205.000 million vs $200.598 million analyst estimate.
01-07 20:21
Kamada Affirms FY2025 Sales Guidance of $178.000M-$182.000M vs $181.137M Est
Kamada (NASDAQ:KMDA) affirms FY2025 sales outlook from $178.000 million-$182.000 million to $178.000 million-$182.000 million vs $181.137 million estimate.
01-07 20:21
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
Kamada Ltd. forecasts 2026 revenues of $200-$205 million and adjusted EBITDA of $50-$53 million, reflecting 13% and 23% increases respectively from 2025 mid-point guidance. Growth is driven by organic expansion of its commercial product portfolio, including U.S. sales and ex-U.S. sales of key products like KAMRAB® and GLASSIA®. The company also prioritizes M&A and business development to enhance its product portfolio and long-term growth. Kamada ...
01-07 12:00
Kamada Wins $10–$14 Million Extension of Canadian Plasma-Product Tender
Kamada ( ($IL:KMDA) ) has shared an announcement. On December 18, 2025, Kamada ...
2025-12-18 20:27
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Kamada Reiterates its 2025 Revenue Guidance of $178M-$182M Vs. Consensus Of $180.66M, And Adjusted EBITDA of $40M-$44M
Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026
2025-12-08 20:08
Kamada To Discontinue Phase 3 InnovAATe Trial As Prespecified Interim Futility Analysis Shows The Trial Of Inhaled AAT For Alpha-1 Antitrypsin Deficiency Is Unlikely To Demonstrate A Statistically Significant Benefit In Its Primary Endpoint
Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA, its AAT-IV
2025-12-08 20:06
Kamada Affirms FY2025 Sales Guidance of $178.000M-$182.000M vs $180.659M Est
Kamada (NASDAQ:KMDA) affirms FY2025 sales outlook from $178.000 million-$182.000 million to $178.000 million-$182.000 million vs $180.659 million estimate.
2025-11-10 20:24
Kamada Q3 EPS $0.09 Misses $0.10 Estimate, Sales $47.010M Beat $45.811M Estimate
Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.10 by 7.22 percent. This is a 28.57 percent increase over earnings of $0.07 per share from the same
2025-11-10 20:11
